The discontinuation of propoxyphene-containing analgesics, such as Darvocet, from the pharmaceutical market stemmed primarily from safety concerns identified through post-market studies. These studies revealed a significantly increased risk of serious cardiac events, including arrhythmias, associated with the drug’s use, even at therapeutic doses.
The presence of propoxyphene carried the potential for fatal overdoses, particularly when combined with alcohol or other central nervous system depressants. Furthermore, the analgesic efficacy of propoxyphene was questioned, with some studies suggesting it offered minimal pain relief compared to other available options. This combination of limited efficacy and heightened safety risks led to increased scrutiny from regulatory agencies.
